Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The tumor-suppressor protein p53, encoded by TP53, inhibits tumorigenesis by inducing cell-cycle arrest, senescence, and apoptosis. Several genetic polymorphisms exist in TP53, including a proline to arginine variant at amino acid 72 (P72 and R72, respectively); this polymorphism alters p53 function. In general, the P72 variant shows increased ability to induce cell-cycle arrest, whereas the R72 variant possesses increased ability to induce apoptosis, relative to P72. At present, the underlying mechanisms for these functional differences are not fully understood. Toward elucidating the molecular basis for these differences, a gene-expression microarray analysis was conducted on normal human fibroblast cells that are homozygous for P72 and R72 variants, along with subclones of these lines that express a p53 short hairpin (shp53). Approximately three dozen genes were identified whose transactivation is affected by the codon 72 polymorphism. One of these is the tripartite-motif family-like 2 (TRIML2) gene, which is preferentially induced by the R72 variant. Importantly, the accumulated data indicate that TRIML2 interacts with p53, and facilitates the modification of p53 with SUMO2. TRIML2 also enhances the ability of p53 to transactivate a subset of proapoptotic target genes associated with prolonged oxidative stress, including PIDD, PIG3 (TP53I3), and PIG6 (PRODH). These data indicate that TRIML2 is part of a feed-forward loop that activates p53 in cells expressing the R72 variant, particularly after prolonged stress. Implications: The defined actions of TRIML2, in part, explain the underlying molecular basis for increased apoptotic potential of the R72 variant of p53. Mol Cancer Res; 13(2); 250–62. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 2×
“Hct116 p53 WT and Hct116 p53 / cells were provided by Bert Vogelstein from Johns Hopkins School of Medicine (13).”
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“The LIMMAmodule in the Open Source R/Bioconductor package was used in the computations (16).”
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · cited 1×
“The p53 tumor-suppressor gene (TP53) is inactivated by mutation in more than half of human cancers (1).”
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · cited 10×
“Mol Cancer Res; 13(2) February 2015 Molecular Cancer Research 258”
InfluentialDistinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
Ginkgolic Acid Inhibits Protein SUMOylation by Blocking Formation of the E1-SUMO Intermediate
Fukuda, I., Ito, A., Hirai, G., Nishimura, S., Kawasaki, H., Saitoh, H., Kimura, K.-I., Sodeoka, M., & Yoshida, M. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.01.009 · Cited by 355
Trim24 targets endogenous p53 for degradation
Allton, K., Jain, A. K., Herz, H.-M., Tsai, W.-W., Jung, S. Y., Qin, J., Bergmann, A., Johnson, R. L., & Barton, M. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813177106 · Cited by 292 · cited 1×
“TRIM24, TRIM28, TRIM29 (also known as ataxia-telangiectasia group D complementing, or ATDC) and TRIM39 all inhibit p53 activity by increasing p53 degradation and/or nuclear export, largely by controlling p53 ubiquitylation (39-42).”
Another fork in the road—life or death decisions by the tumour suppressor p53
Carvajal, L. A., & Manfredi, J. J. (2013) · The EMBO Reports · doi:10.1038/embor.2013.25 · Cited by 149
Wu, S., & Chiang, C. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.83 · Cited by 125
Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells
Obad, S., Brunnström, H., Vallon-Christersson, J., Borg, Å., Drott, K., & Gullberg, U. (2004) · Oncogene · doi:10.1038/sj.onc.1207524 · Cited by 90 · cited 1×
“C, flow cytometric analysis of Annexin V–positive cells in Hct116 cells stably infected with vector or sh-A of TRIML2, following 24, 72, or 96 hours (36) of treatment with 5-FU (5 mmol/L).”
Cited by
p53 signaling in cancer progression and therapy
Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., Morrione, A., Giordano, A., & Cenciarelli, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02396-8 · Cited by 588
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
“Most p53 anti-apoptotic functions happen in the nucleus, especially under resting conditions.(214,215) p53 is normally SUMOylated at a single site, K386, by the protein inhibitor of activated stat (PIAS) family members and Topors.”
BackgroundCas9 activates the p53 pathway and selects for p53-inactivating mutations
Enache, O. M., Rendo, V., Abdusamad, M., Lam, D., Davison, D., Pal, S., Currimjee, N., Hess, J., Pantel, S., Nag, A., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0623-4 · Cited by 285
TRIMming p53’s anticancer activity
Elabd, S., Meroni, G., & Blattner, C. (2016) · Oncogene · doi:10.1038/onc.2016.33 · Cited by 43
Metadata
- Authors
- Kung, C.-P., Khaku, S., Jennis, M., Zhou, Y., & Murphy, M. E.
- Venue
- Molecular Cancer Research
- Published
- 2015-02-01
- Volume
- 13
- Issue
- 2
- Pages
- 250-262
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2168933846
- Cited by
- 57
- References
- 10
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-14-0385
- The paper
- Kung, C.-P., Khaku, S., Jennis, M., Zhou, Y., & Murphy, M. E. (2015). Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-14-0385
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.